GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

First Tracks Biotherapeutics TRAX · USD

US listing · 🇺🇸 United States

Compare

49.70

+3.76%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$166.1m

FY2023FY2025

Free cash flow

−$143.0m

FY2023FY2025

Shareholders' equity

$287.5m

FY2023FY2025

Income statement

Fiscal years

FY2025FY2024FY2023
Gross profit−$139.6m−$152.3m—
Research and development$139.6m$152.3m$97.6m
Operating income−$179.0m−$181.1m−$118.5m
Net income−$166.1m−$163.7m−$106.2m
Diluted earnings per share-4.78-4.71-3.05

Balance sheet

At each fiscal year end

FY2025FY2024FY2023
Total assets$330.5m$441.9m$444.1m
Cash and short-term investments$311.6m$385.4m$390.9m
Total liabilities$43.1m$50.3m$34.3m
Debt$2.1m$1.9m$1.8m
Shareholders' equity$287.5m$391.6m$409.8m
Shares outstanding35m35m35m

Cash flow

Fiscal years

FY2025FY2024FY2023
Cash from operations−$142.9m−$125.8m−$93.0m
Capital spending−$87,000−$358,000−$807,000
Free cash flow−$143.0m−$126.2m−$93.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Mar 2025
Gross profit−$207,000——
Operating income−$34.9m−$52.8m−$51.3m
Net income−$33.4m−$50.5m−$47.2m
Diluted earnings per share-0.94-1.43-1.36
Cash from operations−$31.0m−$32.0m−$45.0m
Total assets$183.1m$290.6m—
Cash and short-term investments$168.0m$286.5m$385.4m
Debt$2.4m——
Shareholders' equity$168.8m$257.5m$391.6m

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.